Skip to content
value.today
Boundless Bio, Inc. logo

Boundless Bio, Inc.

BOLD
$59 Mmarket cap on Oct 29, 2026
Compare
World rank
#20,669
Revenue
—
For year ending December-2025
Net income
$-58 M
SEC filing
Employees
28
As of March 8, 2026
SEC filing

Boundless Bio, Inc. in brief

Boundless Bio, Inc. is a listed company in the Biotechnology industry, based in La Jolla, California, USA. Its market value was $59 M on 29 October 2026, which makes it the 20,669th largest listed company in the world and the 3,788th largest in the USA on this site. It employs about 28 people and Zachary Hornby is its chief executive. Its shares trade under the symbol BOLD (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Boundless Bio, Inc.

We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.

ecDNA are large circular units of nuclear DNA that are a primary mechanism of gene amplification and are detected only in cancer cells, not in healthy cells. Despite tremendous advancements in treating cancer broadly, patients with oncogene amplified cancers generally derive little benefit from existing therapies, such as molecular targeted therapies or immunotherapies, and have worse survival rates than patients without oncogene amplification. Using our proprietary Spyglass platform, we identify targets essential for ecDNA functionality in oncogene amplified cancer cells, then design and develop small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets, with the aim to prevent cancer cells from using chromosomal instability (CIN) and ecDNA amplification biology to grow, adapt, and become resistant to existing therapies. Instead of directly targeting the proteins produced by amplified oncogenes, which is the approach of traditional targeted therapies, our ecDTx are intended to be synthetic lethal in tumor cells reliant on ecDNA amplification biology. In the context of drug development, synthetic lethality is a therapeutic approach wherein using a drug to inhibit one target is lethal to cancer cells harboring a specific genetic alteration to a second target, but not lethal to healthy cells that lack the genetic alteration to the second target.

From the company's annual report filed with the US SEC: read the report

Boundless Bio, Inc. timeline

2 events, 2020–2024
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 28 March 2024; shares registered for exchange trading on 22 March 2024.

Events of Boundless Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$17 M$35 M$52 M$69 M

World rank over time

▼ down 1,993 places since 2026
2026-08-01: #18749#18,74920262026-10-08: #20593#20,59320262026-10-29: #20742#20,7422026

Rank in USA: #3,644 (Aug 2026) · #3,747 (Oct 2026) · #3,791 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-80.0%
Net margin
—
Operating margin
—
Return on equity
-59.0%
Liabilities / assets
37.2%
Profit per employee
$-2.1 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue —, net income $-49M—FY23Fiscal year ending Dec 2024: revenue —, net income $-65M—FY24Fiscal year ending Dec 2025: revenue —, net income $-58M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-64M$-58M—
Dec 2024——$-73M$-65M—
Dec 2023——$-55M$-49M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-47M$1M$-47M$-2.60—
Dec 2024$-61M$3M$-63M$-3.85—
Dec 2023$-47M$1M$-47M$-40.65—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-16M—Dec ’24Three months to Mar 2025: revenue —, net income $-16M—Mar ’25Three months to Jun 2025: revenue —, net income $-16M—Jun ’25Three months to Sep 2025: revenue —, net income $-14M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-13M—Dec ’25Three months to Mar 2026: revenue —, net income $-14M—Mar ’26Three months to Jun 2026: revenue —, net income $-24M—Jun ’26Three months to Sep 2026: revenue —, net income $-5M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Boundless Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-64 M
Net income
$-58 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$157 M
Total liabilities
$58 M
Total equity
$99 M

As of December-2025

Top 42 institutional investors in Boundless Bio, Inc.#

As of Sep 30, 2026
42 institutions held 15.5 M shares (about 65.8% of the shares outstanding) on Sep 30, 2026. The ten largest hold 56.3%. Filings read through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Boundless Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Tang Capital Management LLC2,840,635+280,760 (+10.97%)12.03%$7 MNov 16, 2026
2ARCH Venture Management, LLC2,694,0950 (0.00%)11.41%$7 MNov 16, 2026
3FMR LLC2,564,355-16,700 (-0.65%)10.86%$6 MNov 10, 2026
4ADAR1 Capital Management, LLC1,893,439-74,777 (-3.80%)8.02%$5 MNov 16, 2026
5Cormorant Asset Management, LP940,000-60,000 (-6.00%)3.98%$2 MNov 16, 2026
6Vanguard Capital Management LLC597,192-17,731 (-2.88%)2.53%$1 MNov 13, 2026
7Wellington Management Group LLP556,2330 (0.00%)2.36%$1 MNov 16, 2026
8Renaissance Technologies LLC493,500+21,930 (+4.65%)2.09%$1 MNov 12, 2026
9Two Sigma Investments, LP375,399New1.59%$1 MNov 16, 2026
10Acadian Asset Management LLC347,173+200,416 (+136.56%)1.47%$1 MNov 9, 2026
11Alyeska Investment Group, L.P.300,0000 (0.00%)1.27%$1 MNov 16, 2026
12China Universal Asset Management Co., Ltd.233,300+216,400 (+1280.47%)0.99%$1 MOct 28, 2026
13Superstring Capital Management LP206,242+150,886 (+272.57%)0.87%$1 MNov 16, 2026
14RBF Capital, LLC200,0000 (0.00%)0.85%$1 MNov 13, 2026
15Citadel Advisors LLC158,263+13,214 (+9.11%)0.67%$0 MNov 16, 2026
16Ensign Peak Advisors, Inc133,594-26,241 (-16.42%)0.57%$0 MNov 12, 2026
17Geode Capital Management, LLC129,672+12,936 (+11.08%)0.55%$0 MNov 6, 2026
18Vanguard Fiduciary Trust Co108,415+43,279 (+66.44%)0.46%$0 MNov 13, 2026
19State Street Corp100,662+84,700 (+530.64%)0.43%$0 MNov 12, 2026
20BlackRock, Inc.85,786-2,709 (-3.06%)0.36%$0 MNov 13, 2026
21Bridgeway Capital Management, LLC77,500-50,500 (-39.45%)0.33%$0 MNov 16, 2026
22XTX Topco Ltd70,912+37,551 (+112.56%)0.30%$0 MNov 16, 2026
23Rangeley Capital, LLC68,000-6,000 (-8.11%)0.29%$0 MNov 16, 2026
24Marshall Wace, LLP54,031New0.23%$0 MNov 13, 2026
25Stonepine Capital Management, LLC52,547-102,048 (-66.01%)0.22%$0 MNov 13, 2026

All 42 institutional investors: 26 to 42, with who bought and sold →

Mutual funds holding Boundless Bio, Inc.#

12 funds hold shares worth $4 M (about 9.2% of the company). Since their previous reports 5 added shares and 2 sold, buying $0 M net.
Mutual funds holding Boundless Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Growth Company FundFidelity Management & Research Company LLC900,270$1 M3.8%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.445,181$1 M1.9%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.152,011$0 M0.64%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Growth Company K6 FundFidelity Management & Research Company LLC226,498$0 M0.96%<0.01%−1.3%May 31, 2026
🇺🇸 Fidelity Series Growth Company FundFidelity Management & Research Company LLC202,816$0 M0.86%<0.01%−13%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors58,851$0 M0.25%<0.01%+39%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC50,500$0 M0.21%0.09%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC82,655$0 M0.35%<0.01%+22%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.17,731$0 M0.08%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC15,411$0 M0.07%<0.01%+40%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC8,946$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,089$0 M0.02%<0.01%+38%Jun 30, 2026

As of Jun 30, 2026

Insider trading at Boundless Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$2.0 M
37 purchases, 1 insider
Sold, 12 months
$94 K
3 sales, 3 insiders
Net, 12 months
$1.9 M
open market only
Insiders on file
9
since
$8.2 M-$54 K$0Apr 2024: bought $8.2 M (8 trades), sold $0 (0 trades)Apr 24Jun 2026: bought $781 K (8 trades), sold $0 (0 trades)JunJul 2026: bought $734 K (14 trades), sold $40 K (2 trades)JulAug 2026: bought $0 (0 trades), sold $54 K (1 trades)AugOct 2026: bought $427 K (8 trades), sold $0 (0 trades)OctNov 2026: bought $65 K (7 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Boundless Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kevin Tang10% ownerBuyindirect+12,417$2.400$30 K3.05 MForm 4
filed Kevin Tang10% ownerBuyindirect+1,395$2.400$3 K3.04 MForm 4
filed Kevin Tang10% ownerBuyindirect+249$2.400$5983.04 MForm 4
filed Kevin Tang10% ownerBuyindirect+1,700$2.400$4 K3.04 MForm 4
filed Kevin Tang10% ownerBuyindirect+8,390$2.400$20 K3.03 MForm 4
filed Kevin Tang10% ownerBuyindirect+517$2.400$1 K3.03 MForm 4
filed Kevin Tang10% ownerBuyindirect+2,255$2.400$5 K3.02 MForm 4
filed Kevin Tang10% ownerBuyindirect+10,707$2.400$26 K3.02 MForm 4

Markets and events: Boundless Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
790,294
3.5% of shares · 5.06 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-20 reverse split

Trading halts

  • 2026-06-23 11:25 UTC, code T3, resumed 11:50 UTC
  • 2026-01-20 11:55 UTC, code T3, resumed 12:30 UTC

Fails to deliver

  • : 6,677 shares at $2.50
  • : 149 shares at $2.44
  • : 5,254 shares at $2.64
  • : 980 shares at $2.62
  • : 1,290 shares at $2.83

Boundless Bio, Inc. scorecard#

Passes 2 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 4
  • Growth0 of 1
  • Profitability0 of 2
  • Financial health1 of 2
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Boundless Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Boundless Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Research and development455543
General and administrative191812
Operating expenses647355
Operating income−64−73−55
Interest and finance income5.47.95.3
Other non-operating income (expense)5.47.95.4
Income tax00—
Net income including minority interests−58−65−49
Net income attributable to shareholders−58−65−49
Earnings per share, basic-2.60-3.85-40.65
Earnings per share, diluted-2.60-3.85-40.65
Shares, weighted average (basic)22171.2
Shares, weighted average (diluted)22171.2
Balance sheet
Cash and cash equivalents182724
Short-term investments9012697
Other current assets2.02.33.5
Current assets110154124
Property, plant and equipment3.24.32.6
Right-of-use (leased) assets44472.0
Total assets157206130
Accounts payable1.51.32.2
Current liabilities138.19.4
Lease liabilities (non-current)4648—
Total liabilities58569.4
Retained earnings−260−201−136
Shareholders' equity99151−127
Total equity99151−127
Total liabilities and equity157206130
Shares outstanding2222r0.0r
Cash-flow statement
Depreciation and amortization1.31.11.0
Share-based compensation6.17.53.3
Cash from operating activities−47−61−47
Capital expenditure−0.5−2.5−0.6
Cash from investing activities38−26−38
Cash from financing activities0.19098
Change in cash−8.72.913
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

Events at Boundless Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 2 · Change in control 1 · Directors and officers 5 · Material agreement 3 · Agreement ended 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

Boundless Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Material agreement8-K
RestructuringChange in controlDirectors and officersMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Results announced8-K
Agreement endedNew debt8-K
Directors and officersResults announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Restructuring8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

As of Aug 28, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Boundless Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$100 MNo. 3$50 to $250 million26equitySEC
Apr 2021$106 MNo. 2$50 to $250 million28equitySEC
Aug 2018$23 MNo. 1$10 to $50 million23equitySEC

Layoffs at Boundless Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
1 notices and filings
People, all years
0
2025–2026
Latest
—
2026-06-22
Boundless Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2026···········—
2025············—
Boundless Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

How Boundless Bio, Inc. compares in Biotechnology

  • Market cap$59 M · higher than 28% of 726
  • Price / book0.6× · lower than 89% of 534
  • FCF yield-80.0% · higher than 13% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Boundless Bio, Inc.🇺🇸$59 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 8, 2026
Profile updated:
Nov 21, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Boundless Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Boundless Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Boundless Bio, Inc.? Suggest a correction